Skip to main content

Advertisement

Table 2 Subgroup analysis of the relation between MPV and DR patients

From: The relationship between mean platelet volume and diabetic retinopathy: a systematic review and meta-analysis

Subgroup Study No. of studies SMD 95% CI Heterogeneity
P value I2 (%)
DR vs control
 Location Turkey 7 0.66 0.42–0.90 = 0.003 70
China 3 0.94 0.49–1.40 = 0.005 81
India 2 1.82 1.09–2.56 = 0.003 70
 Study quality High 11 0.79 0.57–1.01 < 0.0001 76
Low 2 4.53 − 0.14 to 9.21 < 0.00001 99
DR vs T2DM without DR
 Location Turkey 7 0.24 0.09–0.40 = 0.11 42
China 2 0.33 0.09–0.56 = 0.68 0
India 2 0.87 0.49–1.25 = 0.23 30
 Study design Case–control 10 0.76 0.17–1.35 < 0.00001 97
Cross-sectional 2 0.37 0.11–0.62 = 0.95 0
 Study quality High 10 0.30 0.15–0.45 = 0.03 51
Low 2 2.36 − 0.79 to 5.51 < 0.00001 99
 DR sub-type NPDR vs control 4 0.41 0.16–0.65 = 0.182 38.3
PDR vs control 4 0.81 0.48–1.14 = 0.031 66.1
NPDR vs T2DM without DR 3 0.04 − 0.16 to 0.24 = 0.642 0
PDR vs T2DM without DR 3 0.48 0.28–0.68 = 0.349 5.1
PDR vs NPDR 4 0.41 0.17–0.64 = 0.193 36.6
Intervalsa
 ≤ 60 min DR vs control 3 0.39 0.20–0.58 = 0.60 0
DR vs T2DM without DR 2 0.02 − 0.25 to 0.30 = 0.18 43
 > 60 min DR vs control 2 0.99 0.67–1.31 = 0.19 41
DR vs T2DM without DR 2 0.37 0.15–0.58 = 0.53 0
  1. MPV mean platelet volume, DR diabetic retinopathy, T2DM without DR type 2 diabetic mellitus without diabetic retinopathy, NPDR non-proliferative diabetic retinopathy, PDR proliferative diabetic retinopathy, SMD standard mean difference, CI confidence interval
  2. aIntervals of MPV collection and measurement